Tag Archives: HCV

Gilead Says Spinoff Of HCV Business Is “Not High On List Of Priorities”

There was much investor chatter last month that Gilead Sciences(GILD) could unlock value by splitting its Hepatitis C business from its HIV business.  RBC Capital advanced the case in a note RBC Capital suggested the drugmaker would be better off cutting its businesses right down the middle, saying that shares could jump by as much as 40% if… Read More »